The effects of sustained virological response to direct‐acting anti‐viral therapy on the risk of extrahepatic manifestations of hepatitis C infection
暂无分享,去创建一个
[1] A. Moorman,et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes , 2019, Alimentary pharmacology & therapeutics.
[2] M. Stepanova,et al. Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia , 2019, Alimentary pharmacology & therapeutics.
[3] Ding‐Shinn Chen,et al. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection , 2018, Alimentary pharmacology & therapeutics.
[4] D. Thabut,et al. Long‐term Efficacy of Interferon‐Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[5] H. El‐Serag,et al. Real‐world effectiveness of elbasvir/grazoprevir In HCV‐infected patients in the US veterans affairs healthcare system , 2018, Journal of viral hepatitis.
[6] D. Vergani,et al. Interferon‐free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis , 2018, Alimentary pharmacology & therapeutics.
[7] P. Cacoub,et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis , 2018, Gut.
[8] E. Bugianesi,et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents , 2018, Journal of medical virology.
[9] Z. Younossi,et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France , 2018, Alimentary pharmacology & therapeutics.
[10] A. Federico,et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkin's lymphoma , 2018, Hepatology.
[11] H. Kokuryu,et al. Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c , 2017, Digestion.
[12] L. Sticchi,et al. Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy , 2017, The Journal of antimicrobial chemotherapy.
[13] G. Ioannou,et al. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus , 2017, Diabetes Care.
[14] J. Kramer,et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection , 2017, Gut.
[15] K. Anderson,et al. Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda , 2017, The American journal of the medical sciences.
[16] D. Klatzmann,et al. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. , 2017, Gastroenterology.
[17] R. Bruno,et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. , 2016, Blood.
[18] L. Petraccia,et al. Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia , 2016, Hepatology.
[19] S. Pol,et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. , 2016, Annals of the rheumatic diseases.
[20] G. Ioannou,et al. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. , 2016, Gastroenterology.
[21] M. Stepanova,et al. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. , 2016, Gastroenterology.
[22] D. Sautereau,et al. HCV‐associated B‐cell non‐Hodgkin lymphomas and new direct antiviral agents , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[23] K. Reddy,et al. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus , 2015, Hepatology.
[24] H. El‐Serag,et al. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. , 2008, Journal of hepatology.
[25] H. El‐Serag,et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. , 2007, JAMA.
[26] L. Dal Maso,et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. , 2018, Clinical and experimental rheumatology.
[27] H. Masur,et al. No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV , 2017, The Journal of infectious diseases.
[28] E. Morra,et al. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. , 2015, Journal of hepatology.
[29] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .